Studies in animals indicate that the half-life (~) of SHC i s longer (2-4 hr s ) t han that o f other polypeptide hormones . This i s believed t o be due t o the fact that SHe circulates as part of a binding protein complex. St udies of the t~of SHC in b.anans ha ve not been possible due to the s carcit y of purified SHC. We have estimated the t~of SHC in 11 c hi l dr en (8M , 3F) with GH deficiency. After 2 baseline s er um samples wer e obtained, ea ch child received 5 doses of NPA hGH (0.1 u/kg/dose) at 12 hr intervals. Serum samples were obtained at 24 hrs and 48 hrs of treatment and at 6 hr intervals aft er t he last dose of hGH. Total SHC was determined on acid-ethano l ex tracted samples ua in g an RIA spe cific for SHe. The t~for SHC disappearance was 18 .7 ± 2.6 hrs (x ± SEM). T~was not correlated with age , bone age or peak SHC . However, the time elapsed from the l aat hG H injection to SHC •~peak SHC was corr elated with bone age (r · 0.67, p 0.05) . In 8 children , growth velocities on hGH are available (8 . 2 ± 2 . 5 en/ yr) . Growth velocity was not significantly correlated with bone age, pea k SHe or t~. Conclusion: The t~of SHC in GH deficient children is considerabl y longer than the t~observed in small animals. The prolonged t~of SHC may partiall y explain t he success of present GH treatment reg imens in pr omoting skeletal growth.
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The purpose of this study was t o compare the bioactivity (8 M) and the bi ndi ng ac tivi ty (I LA) o f soma tcmedin in 11 chil dr en wi th growth retardat i on and persisten t GH secretion aft er cranial i r radiation for medulloblastoma o r he ad and ne ck tumors . Children aged 6-12 yr, first se e n 16-54 mo after i r r adi at i on were i nve s t i ga ted over periods of 6 -36 mo. Each p atient at inverval s of 3 me or morũ nderwent 2 to 4 arginine-insulin tests with determinations of GU, SM by the porcine cartilage bioassay and ILA by RRA after plasma acid ge l filtration . GH peak value s were distributed from severe (5 ng/ml n = 5 ). to partial (5-1 0 ng/ml n = 13) or norma l range (10 ng/ml n = 7 l. Al l SH va lues were l ow « 0 .5 U/ml l . Hean ILA wa s lower than control bu t signi fica nt l y higher than values obtained in idiopathi c hypopituita rism (IH) U/ml I r r adia t ed (n = 18) I B (n = 5) SM 0 . 38 ± 0 .04 0.27 ± 0.05 NS ILA RRA 0. 67 ± 0. 09 0.3 1 ± 0.06
In co nclusion, i n ch ildren wi th growth retardation after crani al irradi ation im pa i r e d GH secretion was associated with SM in the hypop i t uitary range while ILA was only sl i ghtly decreased . Thi s is another cl inical example of the diffi culty i n evaluating somatomedin a c t ivities in growth retardation. D. O. SOBEL. , J . P. GUTAI , B. S. RABIN· , B.J. HONDI NO· , P. FIREMAN•• Unive rs ity of Pittsburgh School of Hedi cine, Pittsburgh , PA. Cel l mediated immunit y t o pitu ita r y ex t rac ts i n hy popi t ui tari sm.
To ob t ain evidence of aut oimmun i ty in ch i l dr en wi t h id i opat hic hypopituita ri sm, lymphocyte re ac tivi ty to pituitary extract in 9 normal s ubjec ts and 3 child ren wi th id iopathic hypopituitari sm was determined . Lymphoc yt e reac t ivity to t hyroid extract was also s tudied. St andard lymphoblast i c transforma t io n t es t i ng by thymidine incorporat ion was per formed wi th crude human pituitary ex t r ac t at concent r ations of 2.6 or 5.0~g protein/ml & 26 or 50~g/ml . For each se t of replicate well s , the arithmetic mean of the s qua r e root counts pe r minute (~ICPH) was calculated . Thymidine incorporation was recorded as the difference of the test counts from the cont r ol (~~.~~to 2 .5/5.0~g/ml in 9 normal subjects was -6. 0 (SO+ 6 . 9). The~~to 26/50~g/ml extract was 0 .66 (S0+8 . 2) . One chi l d ha d~~· 3 4 to the h igher extract concent rat i on whi ch wa s >95% tolerance l~mi t s of normal s ubject s, 6 mont hs l a t e r the~~·40 to the lower extract con centrat ion (>95% conf id enc e limit s ) . This chi l d had no "significant~~to thyroid ext ract . He ha s a lopecia dys t r ophic nail s and T and B cell dysfunc tion.~~t o pi t ui t ary extract to t wo other childr en were within normal limits. In concl us i on we de s cribe an invit ro test to det ect ce l l ul a r hype rsens itivity to p itu itary ext r act for pa t i ents with hypopituit aris m. We report I of 3 c hi l dr en tested with pers i stent lymphocyte react ivity which a ppea r s to be organ s pe c i f i c . Cl ini ca l and labora t or y Product i on of human growth ho rmone by bac ter ia har bo r in g a pLa smid ge ne inc reas es the po t e n t ia l a va i l ab i l i t y o f the ho rmone fo r human clinical us e . The effi c a cy of t his mate ri a l has bee n determin e d by growth p r omo t i ng eff ects i n rats a nd cl in i c a l c hemi st r y pa r ameters in r a t s a nd monke y s. Compa ri so n o f t he pharmac okine t i cs of the hormone adminis t ere d i nt ra mu sc u la r l y or sub-cut an eously ind i c ates t ha t essentiall y simi l a r eff e c t s are achie ved . Other b i och emi c al propert ie s al s o indica t e t hat the sub-cu t an e ou s route is no t a s soc i at ed wi t h potent ial adve r se effec t s , s uppo rti ng use o f t he mater ial f o r a varie ty of c linica l in d ic ations.
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Stunted growth due to peripheral res istance to SOlliltomedin, a new syndrom . Up to now small stature with high plasma-hGi i s known only as Laron-1;ype dwarfism, caused by insufficient response of somatomedin (SM)-production to hGi. Recently we observed a dwarf with constantly elevated levels of hGi and of SM as well. Methods: hGl ace, to Sch~nberg (1972) , SM acc. to van den Brande &Caju (1974) 
is a 15 mo . old girl of healthy parents who cl inically resembles a pituitary dwarf. Length 60 cm (corresp. to age 3 mo.), weight 5.5 kg (",3 mo.), bone age 11 mo . With 5 mo., basal hGi was 36.4 nglml, after arginine max. 46.6 nglml. Blood glucose dropped to 26 mgS under arginine. With 10 mo . basal hGi was 58.2 and 65.5 rrg/ ml, resp .• Basal SM-Ievels were 1;99 and 2.03 u/ml (normal mean for age 0.41 utml). Stimulation with hGi caused no further rise.-Biological inactivi1;y of the hormones measured seems improbable, because SM-acti vity was determined biologically and the high SMlevels presumably are the result of the elevated hGH-secretion . Two other patients who clinically exhibited delayed growth and adolescence showed normal basal hGl-levels but significantly increased spontaneous hGi-secretion by night and, i n addition, high plasma-SM. Conclusion. In the first case, a pseudo-hypopituitary dwarf with high pJasma-hGi and -SM, absolute peripheral res istance against SM seems to be the most plausible explanation . In the 2 other cases, a certain degree of non-responsiveness to SM may playa r6le. 
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Dept . of Ped ia tr ics, Stanford Universi t y Med i cal Center, Stanford, Cal ifornia USA. Synthetic hGH causes both inc reased somatomed in levels and insulin resistance in humans.
The supply of human pituitary growth hormone (hGH) available has been limited by the number of donors. RecentlY, methionyl-hGH (Genent ech ) has been synthesized by recombinant DNA technique s . W e have compared syn theti c methionyl-hGH with pi tui t a ry hGH in twelve normal ad ult male volunteers. Each patient was given 4 da ily doses of 16 U of each hGH with a 10 day period between hGH preparations . Somatomedin-C (SH-C) by RIA was determined da i ly . Glucose t olerance tests were done prior to the first and after the fourth injection. The SH-C by RIA increased from a baseline of 1.04 ± 0.07 U/ml to 2 .95 + 0.20 U/ml with methionyl-hGH and from 1.11 + 0 .06 U/ml to 3.08 + 0.19 U/ml with pituitary hGH . The GTT glucose area increased from 348 + 16 mg%-hr to 475 + 30 mg%-hr and the i nsul i n area i ncr e a s ed from-I 33 + 19 uU/ ml-hr to 40 3 + 55 uU/ml-hr with methionyl-hGH. The glucose area i nc r ea s ed from 333 ± 14 mg% -hr to 435 ± 25 mg%-hr and the insulin area increased f r om 110 ± 12 uU/mlhr to 324 + 49 uU/ml-hr with pi tuitary hGH. The equal somatomedin responses are evidence that the synthetic methionyl hGH has f ul l biological activity. The equal changes in glucose metabolism demonstrate that inaulin resis tence is linked to monocomponent synthetic hGH as well as pituitary hGH . These s tudi es open the way for explorations of us e s of methionyl-hGH in human diaease s ta t es and developmental disorders .
